Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Depreciation & Amortization (CF) (2020)

Kalaris Therapeutics (KLRS) has 1 years of Depreciation & Amortization (CF) data on record, last reported at $18000.0 in Q4 2020.

  • For Q4 2020, Depreciation & Amortization (CF) changed N/A year-over-year to $18000.0; the TTM value through Dec 2020 reached $73000.0, changed N/A, while the annual FY2023 figure was $398000.0, 44.95% down from the prior year.
  • Depreciation & Amortization (CF) reached $18000.0 in Q4 2020 per KLRS's latest filing, roughly flat from $18000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $19000.0 in Q2 2020 and bottomed at $18000.0 in Q1 2020.